The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)

This is the report of an open label clinical trial to evaluate the effects of nabilone, an endocannabinoid receptor agonist, on treatment‐resistant nightmares in patients diagnosed with posttraumatic stress disorder (PTSD). Methods: Charts of 47 patients diagnosed with PTSD and having continuing nightmares in spite of conventional antidepressants and hypnotics were reviewed after adjunctive treatment with nabilone was initiated. These patients had been referred to a psychiatric specialist outpatient clinic between 2004 and 2006. The majority of patients (72%) receiving nabilone experienced either cessation of nightmares or a significant reduction in nightmare intensity. Subjective improvement in sleep time, the quality of sleep, and the reduction of daytime flashbacks and nightsweats were also noted by some patients. The results of this study indicate the potential benefits of nabilone, a synthetic cannabinoid, in patients with PTSD experiencing poor control of nightmares with standard pharmacotherapy. This is the first report of the use of nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada) for the management of treatment‐resistant nightmares in PTSD.

[1]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[2]  M. Ware,et al.  Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. , 2006, Pain medicine.

[3]  R. Glass,et al.  Single‐Dose Study of Nabilone in Anxious Volunteers , 1981, Journal of clinical pharmacology.

[4]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[5]  R. Kessler,et al.  Posttraumatic stress disorder in the National Comorbidity Survey. , 1995, Archives of general psychiatry.

[6]  W. Poewe,et al.  Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain , 2006, Journal of Neurology.

[7]  Lan Xiao,et al.  Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. , 2005, The Journal of clinical investigation.

[8]  H. Westenberg,et al.  Pharmacotherapeutic Treatment of Nightmares and Insomnia in Posttraumatic Stress Disorder , 2006, Annals of the New York Academy of Sciences.

[9]  M. Ben Amar,et al.  Cannabinoids in medicine: A review of their therapeutic potential. , 2006, Journal of ethnopharmacology.

[10]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[11]  M M Ohayon,et al.  Sleep disturbances and psychiatric disorders associated with posttraumatic stress disorder in the general population. , 2000, Comprehensive psychiatry.

[12]  Edna B. Foa,et al.  The Validation of a Self-Report Measure of Posttraumatic Stress Disorder , 1997 .

[13]  Michael Davis,et al.  Enhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear , 2005, Neuropsychopharmacology.

[14]  W. Zieglgänsberger,et al.  The endogenous cannabinoid system controls extinction of aversive memories , 2002, Nature.

[15]  S. Gaetani,et al.  Modulation of anxiety through blockade of anandamide hydrolysis , 2003, Nature Medicine.

[16]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[17]  A. Young,et al.  Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential , 2005, Journal of psychopharmacology.

[18]  E. Tzavara,et al.  A role for cannabinoid CB1 receptors in mood and anxiety disorders , 2005, Behavioural pharmacology.

[19]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[20]  C. Ledent,et al.  The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. , 2004, Life sciences.

[21]  L. Fabre,et al.  The Efficacy and Safety of Nabilone (A Synthetic Cannabinoid) in the Treatment of Anxiety , 1981, Journal of clinical pharmacology.

[22]  Clinical practice guidelines. Management of anxiety disorders. , 2006, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[23]  M. Boyle,et al.  Post‐Traumatic Stress Disorder in Canada , 2008, CNS neuroscience & therapeutics.

[24]  M. Lynch.  Preclinical science regarding cannabinoids as analgesics: an overview. , 2005, Pain research & management.

[25]  D. Segal.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) , 2010 .

[26]  M. Koss,et al.  Nightmare frequency in sexual assault survivors with PTSD. , 2002, Journal of anxiety disorders.